社区
首页
集团介绍
社区
资讯
行情
学堂
TigerAI
登录
注册
SquatMachine
IP属地：未知
+关注
帖子 · 6
帖子 · 6
关注 · 0
关注 · 0
粉丝 · 0
粉丝 · 0
SquatMachine
SquatMachine
·
2021-12-06
price not being reflected
Why Moderna Is the Biggest Winner From COVID Boosters So Far<blockquote>为什么Moderna是迄今为止COVID加强剂的最大赢家</blockquote>
It's been roughly three and a half months since the U.S. Food and Drug Administration (FDA) authoriz
Why Moderna Is the Biggest Winner From COVID Boosters So Far<blockquote>为什么Moderna是迄今为止COVID加强剂的最大赢家</blockquote>
看
2,170
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
SquatMachine
SquatMachine
·
2021-12-03
Finally?!!
Didi reintroduces its apps in Apple Store.<blockquote>滴滴在苹果商店重新推出其应用程序。</blockquote>
It's reported that Didi reintroduces its apps in Apple Store. However, Didi said that it was a rumor
Didi reintroduces its apps in Apple Store.<blockquote>滴滴在苹果商店重新推出其应用程序。</blockquote>
看
2,046
回复
评论
点赞
5
编组 21备份 2
分享
举报
SquatMachine
SquatMachine
·
2021-12-02
It's dropping like no tmw... hold?
Moderna shares dipped more than 2% in premarket trading<blockquote>Moderna股价在盘前交易中下跌超过2%</blockquote>
Moderna shares dipped more than 2% in premarket trading as it could be sued over vaccines as court u
Moderna shares dipped more than 2% in premarket trading<blockquote>Moderna股价在盘前交易中下跌超过2%</blockquote>
看
3,444
回复
2
点赞
2
编组 21备份 2
分享
举报
SquatMachine
SquatMachine
·
2021-11-30
Didn't he say earlier it's good to go for 2022???
Moderna stock slid 1.5% in premarket trading<blockquote>Moderna股价在盘前交易中下跌1.5%</blockquote>
Moderna stock slid 1.5% in premarket trading as Moderna CEO said vaccines likely less effective agai
Moderna stock slid 1.5% in premarket trading<blockquote>Moderna股价在盘前交易中下跌1.5%</blockquote>
看
3,279
回复
1
点赞
8
编组 21备份 2
分享
举报
SquatMachine
SquatMachine
·
2021-08-25
lets get some volume in.
Some meme stocks slipped in morning trading<blockquote>一些模因股票早盘下跌</blockquote>
Some meme stocks slipped in morning trading.GameStop,AMC Entertainment,Express,KOSS and Robinhood fe
Some meme stocks slipped in morning trading<blockquote>一些模因股票早盘下跌</blockquote>
看
1,654
回复
1
点赞
5
编组 21备份 2
分享
举报
SquatMachine
SquatMachine
·
2021-07-27
Buy the dip on NIO?
中概股跌幅持续扩大，小鹏汽车跌超15%
7月27日，中概股跌幅持续扩大，小鹏汽车跌超15%，理想汽车跌超11%，拼多多跌超10%，蔚来、哔哩哔哩跌超9%，阿里巴巴、京东、百度跌超5%.
中概股跌幅持续扩大，小鹏汽车跌超15%
看
1,473
回复
评论
点赞
点赞
编组 21备份 2
分享
举报
加载更多
热议股票
{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3577793809591330","uuid":"3577793809591330","gmtCreate":1614954610056,"gmtModify":1706620613837,"name":"SquatMachine","pinyin":"squatmachine","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":5,"headSize":3,"tweetSize":6,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-3","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资合伙人虎","description":"证券账户累计交易金额达到100万美元","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"93.50%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.07.19","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.28","exceedPercentage":"93.76%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":606010283,"gmtCreate":1638800689347,"gmtModify":1638800895996,"author":{"id":"3577793809591330","authorId":"3577793809591330","name":"SquatMachine","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577793809591330","authorIdStr":"3577793809591330"},"themes":[],"htmlText":"price not being reflected","listText":"price not being reflected","text":"price not being reflected","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/606010283","repostId":"1125593879","repostType":2,"repost":{"id":"1125593879","kind":"news","pubTimestamp":1638756575,"share":"https://www.laohu8.com/m/news/1125593879?lang=zh_CN&edition=full","pubTime":"2021-12-06 10:09","market":"us","language":"en","title":"Why Moderna Is the Biggest Winner From COVID Boosters So Far<blockquote>为什么Moderna是迄今为止COVID加强剂的最大赢家</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1125593879","media":"Motley Fool","summary":"It's been roughly three and a half months since the U.S. Food and Drug Administration (FDA) authoriz","content":"<p>It's been roughly three and a half months since the U.S. Food and Drug Administration (FDA) authorized boosters for the COVID-19 vaccine developed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) for certain groups. Around two and half months ago, the agency granted authorizations for boosters for Moderna's (NASDAQ:MRNA) and Johnson & Johnson's (NYSE:JNJ) vaccines, with limitations for which individuals could receive the Moderna booster.</p><p><blockquote>美国已经过去大约三个半月了。美国食品和药物管理局(FDA)授权辉瑞(NYSE：PFE)和BioNTech(纳斯达克：BNTX)为某些群体开发的COVID-19疫苗加强剂。大约两个半月前，该机构批准了Moderna（纳斯达克股票代码：MRNA）和强生公司（纽约证券交易所股票代码：JNJ）疫苗的加强剂，但对个人接受Moderna加强剂的范围有所限制。</blockquote></p><p> A little over two weeks ago, the FDA broadened its Emergency Use Authorization for the Pfizer-BioNTech and Moderna boosters to include all adults ages 18 and older. Overall, close to 42 million Americans have received booster shots.</p><p><blockquote>两周多前，FDA扩大了辉瑞-BioNTech和Moderna增强剂的紧急使用授权，将所有18岁及以上的成年人纳入其中。总体而言，近4200万美国人接受了加强注射。</blockquote></p><p> Which vaccine maker is winning the battle of the boosters so far? It's still early, but Moderna appears to be ahead in several respects</p><p><blockquote>到目前为止，哪家疫苗制造商正在赢得加强剂之战？现在还为时过早，但Moderna似乎在几个方面领先</blockquote></p><p> <b>Analyzing the data</b></p><p><blockquote><b>分析数据</b></blockquote></p><p> More booster doses of the Pfizer-BioNTech vaccine have been given than have been administered for the Moderna and J&J boosters. Pfizer and BioNTech are clearly in the lead on this front.</p><p><blockquote>辉瑞-BioNTech疫苗的加强剂量比Moderna和J&J加强剂量还要多。辉瑞和BioNTech在这方面显然处于领先地位。</blockquote></p><p> You'd expect that more people would have received the Pfizer-BioNTech booster. It's been available for many Americans (including those ages 65 and older) for a month longer than the other two vaccine types.</p><p><blockquote>你会认为会有更多的人接受辉瑞-BioNTech加强剂。许多美国人（包括65岁及以上的人）接种疫苗的时间比其他两种疫苗多一个月。</blockquote></p><p> Also, many more individuals received the Pfizer-BioNTech vaccine initially than received the other two vaccines. A lot of those people chose to receive the booster of the same vaccine that they received for their primary series. The chart below shows how the different vaccines stack up against each other based on the fully vaccinated numbers.</p><p><blockquote>此外，最初接受辉瑞-BioNTech疫苗的人比接受其他两种疫苗的人多得多。这些人中的许多人选择接受与他们在初级系列中接受的相同疫苗的加强剂。下图显示了不同疫苗如何根据完全接种的人数相互叠加。</blockquote></p><p> So why do I maintain that Moderna is the biggest winner with boosters so far and not Pfizer or BioNTech? There are three reasons.</p><p><blockquote>那么，为什么我坚持认为Moderna是迄今为止助推器的最大赢家，而不是辉瑞或BioNTech？原因有三。</blockquote></p><p> First, from a financial standpoint, Moderna's 18 million booster doses made it more money than Pfizer or BioNTech made from their 23.3 million or so booster doses. Moderna doesn't have to split its profits as Pfizer and BioNTech do.</p><p><blockquote>首先，从财务角度来看，Moderna的1800万剂加强剂比辉瑞或BioNTech从2330万剂左右的加强剂中赚的钱还要多。Moderna不必像辉瑞和BioNTech那样分配利润。</blockquote></p><p> Second, Moderna is gaining more traction with boosters than Pfizer-BioNTech or J&J are. A little over 25% of the number of fully vaccinated individuals receiving the primary series of the Moderna vaccine have received Moderna boosters. The ratio is 21.3% for Pfizer-BioNTech.</p><p><blockquote>其次，与辉瑞-BioNTech或强生相比，Moderna在助推器方面获得了更多的关注。在接受Moderna疫苗初级系列的完全接种者中，略高于25%的人接受了Moderna加强剂。辉瑞-BioNTech的这一比例为21.3%。</blockquote></p><p> Third, with the FDA allowing mix-and-match boosters, more people appear to be switching from another vaccine to Moderna than they are to any other vaccine type. For those who initially received the J&J vaccine, 42.5% so far have gone with the Moderna booster versus 31.2% for a Pfizer-BioNTech booster and only 26.2% for a J&J booster.</p><p><blockquote>第三，随着FDA允许混合搭配加强剂，从另一种疫苗转向Moderna的人似乎比转向任何其他疫苗类型的人都多。对于最初接种强生疫苗的人来说，迄今为止，42.5%的人接种了Moderna加强剂，而辉瑞-BioNTech加强剂的比例为31.2%，强生加强剂的比例仅为26.2%。</blockquote></p><p> <b>Why is Moderna winning?</b></p><p><blockquote><b>为什么Moderna会赢？</b></blockquote></p><p> We don't know for sure why Moderna seems to be gaining momentum. However, I have a theory for why it could be happening.</p><p><blockquote>我们不确定为什么Moderna似乎正在获得动力。然而，我有一个理论来解释为什么会发生这种情况。</blockquote></p><p> My hunch is that many Americans have heard that Moderna's efficacy against the delta variant is higher than the efficacy of the Pfizer-BioNTech and Johnson & Johnson vaccines. The initial efficacy of the single-shot J&J vaccine was well below its two messenger RNA vaccine rivals. And the efficacy of the Pfizer-BioNTech vaccine appears to have waned more than the Moderna vaccine has with the rise of the delta variant.</p><p><blockquote>我的预感是，许多美国人听说Moderna对德尔塔变异毒株的疗效高于辉瑞-BioNTech和强生疫苗的疗效。单针强生疫苗的初始效力远低于其两种信使RNA疫苗竞争对手。随着德尔塔变异毒株的崛起，辉瑞-BioNTech疫苗的效力似乎比Moderna疫苗减弱得更多。</blockquote></p><p> I suspect that preliminary data showing that a mix-and-match combination of the Pfizer-BioNTech primary series and a Moderna booster provides a higher efficacy could also be making a difference to some extent. Singapore's minister of health even recently recommended that citizens in the country who initially received the Pfizer-BioNTech vaccine get the Moderna booster.</p><p><blockquote>我怀疑初步数据显示，辉瑞-BioNTech primary系列和Moderna booster的混搭组合提供了更高的疗效，这也可能在某种程度上产生影响。新加坡卫生部长最近甚至建议该国最初接种辉瑞-BioNTech疫苗的公民接种Moderna加强剂。</blockquote></p><p> <b>What really matters</b></p><p><blockquote><b>真正重要的是什么</b></blockquote></p><p> Don't expect Moderna's relative outperformance in boosters to do much for the vaccine stock. Many investors aren't paying attention to the data. And the U.S. has already purchased enough doses from Moderna to meet the demand, including boosters.</p><p><blockquote>不要指望Moderna在加强剂方面的相对优异表现会对疫苗股产生多大影响。许多投资者没有关注这些数据。美国已经从Moderna购买了足够的剂量来满足需求，包括加强剂。</blockquote></p><p> What really matters for Moderna is how strong the longer-term demand will be for its COVID-19 vaccine. The company's efforts fighting the new omicron variant could play a key role in shaping that demand. But the most important factors will be whether or not annual vaccines are required to prevent COVID-19 and, if so, what price Moderna will be able to charge.</p><p><blockquote>对Moderna来说，真正重要的是对其COVID-19疫苗的长期需求有多强劲。该公司对抗新奥密克戎变种的努力可能在塑造这一需求方面发挥关键作用。但最重要的因素将是是否需要每年接种疫苗来预防COVID-19，如果需要，Moderna将能够收取什么价格。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why Moderna Is the Biggest Winner From COVID Boosters So Far<blockquote>为什么Moderna是迄今为止COVID加强剂的最大赢家</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy Moderna Is the Biggest Winner From COVID Boosters So Far<blockquote>为什么Moderna是迄今为止COVID加强剂的最大赢家</blockquote>\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Motley Fool</strong><span class=\"h-time small\">2021-12-06 10:09</span>\n</p>\n</h4>\n</header>\n<article>\n<p>It's been roughly three and a half months since the U.S. Food and Drug Administration (FDA) authorized boosters for the COVID-19 vaccine developed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) for certain groups. Around two and half months ago, the agency granted authorizations for boosters for Moderna's (NASDAQ:MRNA) and Johnson & Johnson's (NYSE:JNJ) vaccines, with limitations for which individuals could receive the Moderna booster.</p><p><blockquote>美国已经过去大约三个半月了。美国食品和药物管理局(FDA)授权辉瑞(NYSE：PFE)和BioNTech(纳斯达克：BNTX)为某些群体开发的COVID-19疫苗加强剂。大约两个半月前，该机构批准了Moderna（纳斯达克股票代码：MRNA）和强生公司（纽约证券交易所股票代码：JNJ）疫苗的加强剂，但对个人接受Moderna加强剂的范围有所限制。</blockquote></p><p> A little over two weeks ago, the FDA broadened its Emergency Use Authorization for the Pfizer-BioNTech and Moderna boosters to include all adults ages 18 and older. Overall, close to 42 million Americans have received booster shots.</p><p><blockquote>两周多前，FDA扩大了辉瑞-BioNTech和Moderna增强剂的紧急使用授权，将所有18岁及以上的成年人纳入其中。总体而言，近4200万美国人接受了加强注射。</blockquote></p><p> Which vaccine maker is winning the battle of the boosters so far? It's still early, but Moderna appears to be ahead in several respects</p><p><blockquote>到目前为止，哪家疫苗制造商正在赢得加强剂之战？现在还为时过早，但Moderna似乎在几个方面领先</blockquote></p><p> <b>Analyzing the data</b></p><p><blockquote><b>分析数据</b></blockquote></p><p> More booster doses of the Pfizer-BioNTech vaccine have been given than have been administered for the Moderna and J&J boosters. Pfizer and BioNTech are clearly in the lead on this front.</p><p><blockquote>辉瑞-BioNTech疫苗的加强剂量比Moderna和J&J加强剂量还要多。辉瑞和BioNTech在这方面显然处于领先地位。</blockquote></p><p> You'd expect that more people would have received the Pfizer-BioNTech booster. It's been available for many Americans (including those ages 65 and older) for a month longer than the other two vaccine types.</p><p><blockquote>你会认为会有更多的人接受辉瑞-BioNTech加强剂。许多美国人（包括65岁及以上的人）接种疫苗的时间比其他两种疫苗多一个月。</blockquote></p><p> Also, many more individuals received the Pfizer-BioNTech vaccine initially than received the other two vaccines. A lot of those people chose to receive the booster of the same vaccine that they received for their primary series. The chart below shows how the different vaccines stack up against each other based on the fully vaccinated numbers.</p><p><blockquote>此外，最初接受辉瑞-BioNTech疫苗的人比接受其他两种疫苗的人多得多。这些人中的许多人选择接受与他们在初级系列中接受的相同疫苗的加强剂。下图显示了不同疫苗如何根据完全接种的人数相互叠加。</blockquote></p><p> So why do I maintain that Moderna is the biggest winner with boosters so far and not Pfizer or BioNTech? There are three reasons.</p><p><blockquote>那么，为什么我坚持认为Moderna是迄今为止助推器的最大赢家，而不是辉瑞或BioNTech？原因有三。</blockquote></p><p> First, from a financial standpoint, Moderna's 18 million booster doses made it more money than Pfizer or BioNTech made from their 23.3 million or so booster doses. Moderna doesn't have to split its profits as Pfizer and BioNTech do.</p><p><blockquote>首先，从财务角度来看，Moderna的1800万剂加强剂比辉瑞或BioNTech从2330万剂左右的加强剂中赚的钱还要多。Moderna不必像辉瑞和BioNTech那样分配利润。</blockquote></p><p> Second, Moderna is gaining more traction with boosters than Pfizer-BioNTech or J&J are. A little over 25% of the number of fully vaccinated individuals receiving the primary series of the Moderna vaccine have received Moderna boosters. The ratio is 21.3% for Pfizer-BioNTech.</p><p><blockquote>其次，与辉瑞-BioNTech或强生相比，Moderna在助推器方面获得了更多的关注。在接受Moderna疫苗初级系列的完全接种者中，略高于25%的人接受了Moderna加强剂。辉瑞-BioNTech的这一比例为21.3%。</blockquote></p><p> Third, with the FDA allowing mix-and-match boosters, more people appear to be switching from another vaccine to Moderna than they are to any other vaccine type. For those who initially received the J&J vaccine, 42.5% so far have gone with the Moderna booster versus 31.2% for a Pfizer-BioNTech booster and only 26.2% for a J&J booster.</p><p><blockquote>第三，随着FDA允许混合搭配加强剂，从另一种疫苗转向Moderna的人似乎比转向任何其他疫苗类型的人都多。对于最初接种强生疫苗的人来说，迄今为止，42.5%的人接种了Moderna加强剂，而辉瑞-BioNTech加强剂的比例为31.2%，强生加强剂的比例仅为26.2%。</blockquote></p><p> <b>Why is Moderna winning?</b></p><p><blockquote><b>为什么Moderna会赢？</b></blockquote></p><p> We don't know for sure why Moderna seems to be gaining momentum. However, I have a theory for why it could be happening.</p><p><blockquote>我们不确定为什么Moderna似乎正在获得动力。然而，我有一个理论来解释为什么会发生这种情况。</blockquote></p><p> My hunch is that many Americans have heard that Moderna's efficacy against the delta variant is higher than the efficacy of the Pfizer-BioNTech and Johnson & Johnson vaccines. The initial efficacy of the single-shot J&J vaccine was well below its two messenger RNA vaccine rivals. And the efficacy of the Pfizer-BioNTech vaccine appears to have waned more than the Moderna vaccine has with the rise of the delta variant.</p><p><blockquote>我的预感是，许多美国人听说Moderna对德尔塔变异毒株的疗效高于辉瑞-BioNTech和强生疫苗的疗效。单针强生疫苗的初始效力远低于其两种信使RNA疫苗竞争对手。随着德尔塔变异毒株的崛起，辉瑞-BioNTech疫苗的效力似乎比Moderna疫苗减弱得更多。</blockquote></p><p> I suspect that preliminary data showing that a mix-and-match combination of the Pfizer-BioNTech primary series and a Moderna booster provides a higher efficacy could also be making a difference to some extent. Singapore's minister of health even recently recommended that citizens in the country who initially received the Pfizer-BioNTech vaccine get the Moderna booster.</p><p><blockquote>我怀疑初步数据显示，辉瑞-BioNTech primary系列和Moderna booster的混搭组合提供了更高的疗效，这也可能在某种程度上产生影响。新加坡卫生部长最近甚至建议该国最初接种辉瑞-BioNTech疫苗的公民接种Moderna加强剂。</blockquote></p><p> <b>What really matters</b></p><p><blockquote><b>真正重要的是什么</b></blockquote></p><p> Don't expect Moderna's relative outperformance in boosters to do much for the vaccine stock. Many investors aren't paying attention to the data. And the U.S. has already purchased enough doses from Moderna to meet the demand, including boosters.</p><p><blockquote>不要指望Moderna在加强剂方面的相对优异表现会对疫苗股产生多大影响。许多投资者没有关注这些数据。美国已经从Moderna购买了足够的剂量来满足需求，包括加强剂。</blockquote></p><p> What really matters for Moderna is how strong the longer-term demand will be for its COVID-19 vaccine. The company's efforts fighting the new omicron variant could play a key role in shaping that demand. But the most important factors will be whether or not annual vaccines are required to prevent COVID-19 and, if so, what price Moderna will be able to charge.</p><p><blockquote>对Moderna来说，真正重要的是对其COVID-19疫苗的长期需求有多强劲。该公司对抗新奥密克戎变种的努力可能在塑造这一需求方面发挥关键作用。但最重要的因素将是是否需要每年接种疫苗来预防COVID-19，如果需要，Moderna将能够收取什么价格。</blockquote></p><p></p>\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.fool.com/investing/2021/12/05/why-moderna-is-the-biggest-winner-from-covid-boost/\">Motley Fool</a></p>\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://www.fool.com/investing/2021/12/05/why-moderna-is-the-biggest-winner-from-covid-boost/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1125593879","content_text":"It's been roughly three and a half months since the U.S. Food and Drug Administration (FDA) authorized boosters for the COVID-19 vaccine developed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX) for certain groups. Around two and half months ago, the agency granted authorizations for boosters for Moderna's (NASDAQ:MRNA) and Johnson & Johnson's (NYSE:JNJ) vaccines, with limitations for which individuals could receive the Moderna booster.\n\nA little over two weeks ago, the FDA broadened its Emergency Use Authorization for the Pfizer-BioNTech and Moderna boosters to include all adults ages 18 and older. Overall, close to 42 million Americans have received booster shots.\n\nWhich vaccine maker is winning the battle of the boosters so far? It's still early, but Moderna appears to be ahead in several respects\nAnalyzing the data\nMore booster doses of the Pfizer-BioNTech vaccine have been given than have been administered for the Moderna and J&J boosters. Pfizer and BioNTech are clearly in the lead on this front.\n\nYou'd expect that more people would have received the Pfizer-BioNTech booster. It's been available for many Americans (including those ages 65 and older) for a month longer than the other two vaccine types.\n\nAlso, many more individuals received the Pfizer-BioNTech vaccine initially than received the other two vaccines. A lot of those people chose to receive the booster of the same vaccine that they received for their primary series. The chart below shows how the different vaccines stack up against each other based on the fully vaccinated numbers.\n\nSo why do I maintain that Moderna is the biggest winner with boosters so far and not Pfizer or BioNTech? There are three reasons.\n\nFirst, from a financial standpoint, Moderna's 18 million booster doses made it more money than Pfizer or BioNTech made from their 23.3 million or so booster doses. Moderna doesn't have to split its profits as Pfizer and BioNTech do.\n\nSecond, Moderna is gaining more traction with boosters than Pfizer-BioNTech or J&J are. A little over 25% of the number of fully vaccinated individuals receiving the primary series of the Moderna vaccine have received Moderna boosters. The ratio is 21.3% for Pfizer-BioNTech.\n\nThird, with the FDA allowing mix-and-match boosters, more people appear to be switching from another vaccine to Moderna than they are to any other vaccine type. For those who initially received the J&J vaccine, 42.5% so far have gone with the Moderna booster versus 31.2% for a Pfizer-BioNTech booster and only 26.2% for a J&J booster.\n\nWhy is Moderna winning?\nWe don't know for sure why Moderna seems to be gaining momentum. However, I have a theory for why it could be happening.\n\nMy hunch is that many Americans have heard that Moderna's efficacy against the delta variant is higher than the efficacy of the Pfizer-BioNTech and Johnson & Johnson vaccines. The initial efficacy of the single-shot J&J vaccine was well below its two messenger RNA vaccine rivals. And the efficacy of the Pfizer-BioNTech vaccine appears to have waned more than the Moderna vaccine has with the rise of the delta variant.\n\nI suspect that preliminary data showing that a mix-and-match combination of the Pfizer-BioNTech primary series and a Moderna booster provides a higher efficacy could also be making a difference to some extent. Singapore's minister of health even recently recommended that citizens in the country who initially received the Pfizer-BioNTech vaccine get the Moderna booster.\n\nWhat really matters\nDon't expect Moderna's relative outperformance in boosters to do much for the vaccine stock. Many investors aren't paying attention to the data. And the U.S. has already purchased enough doses from Moderna to meet the demand, including boosters.\n\nWhat really matters for Moderna is how strong the longer-term demand will be for its COVID-19 vaccine. The company's efforts fighting the new omicron variant could play a key role in shaping that demand. But the most important factors will be whether or not annual vaccines are required to prevent COVID-19 and, if so, what price Moderna will be able to charge.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":2170,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":601845900,"gmtCreate":1638514700795,"gmtModify":1638514700890,"author":{"id":"3577793809591330","authorId":"3577793809591330","name":"SquatMachine","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577793809591330","authorIdStr":"3577793809591330"},"themes":[],"htmlText":"Finally?!!","listText":"Finally?!!","text":"Finally?!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/601845900","repostId":"1149654291","repostType":2,"repost":{"id":"1149654291","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638514400,"share":"https://www.laohu8.com/m/news/1149654291?lang=zh_CN&edition=full","pubTime":"2021-12-03 14:53","market":"us","language":"en","title":"Didi reintroduces its apps in Apple Store.<blockquote>滴滴在苹果商店重新推出其应用程序。</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1149654291","media":"Tiger Newspress","summary":"It's reported that Didi reintroduces its apps in Apple Store.\nHowever, Didi said that it was a rumor","content":"<p>It's reported that Didi reintroduces its apps in Apple Store.</p><p><blockquote>据报道，滴滴在苹果商店重新推出了其应用程序。</blockquote></p><p> However, Didi said that it was a rumor.</p><p><blockquote>不过，滴滴方面表示，这是谣言。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Didi reintroduces its apps in Apple Store.<blockquote>滴滴在苹果商店重新推出其应用程序。</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDidi reintroduces its apps in Apple Store.<blockquote>滴滴在苹果商店重新推出其应用程序。</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-03 14:53</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>It's reported that Didi reintroduces its apps in Apple Store.</p><p><blockquote>据报道，滴滴在苹果商店重新推出了其应用程序。</blockquote></p><p> However, Didi said that it was a rumor.</p><p><blockquote>不过，滴滴方面表示，这是谣言。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"DIDI":"滴滴(已退市)"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1149654291","content_text":"It's reported that Didi reintroduces its apps in Apple Store.\nHowever, Didi said that it was a rumor.","news_type":1,"symbols_score_info":{"DIDI":0.9}},"isVote":1,"tweetType":1,"viewCount":2046,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":603468710,"gmtCreate":1638440850258,"gmtModify":1638440971157,"author":{"id":"3577793809591330","authorId":"3577793809591330","name":"SquatMachine","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577793809591330","authorIdStr":"3577793809591330"},"themes":[],"htmlText":"It's dropping like no tmw... hold?","listText":"It's dropping like no tmw... hold?","text":"It's dropping like no tmw... hold?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/603468710","repostId":"1138497635","repostType":2,"repost":{"id":"1138497635","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638436217,"share":"https://www.laohu8.com/m/news/1138497635?lang=zh_CN&edition=full","pubTime":"2021-12-02 17:10","market":"us","language":"en","title":"Moderna shares dipped more than 2% in premarket trading<blockquote>Moderna股价在盘前交易中下跌超过2%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1138497635","media":"Tiger Newspress","summary":"Moderna shares dipped more than 2% in premarket trading as it could be sued over vaccines as court u","content":"<p>Moderna shares dipped more than 2% in premarket trading as it could be sued over vaccines as court upholds Arbutus patents.</p><p><blockquote>Moderna股价在盘前交易中下跌超过2%，因为法院支持杨梅专利，该公司可能会因疫苗问题被起诉。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/c4b23d228b24ede7e56c373ea5ecd787\" tg-width=\"853\" tg-height=\"622\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> Moderna Inc could face a patent infringement lawsuit over its COVID-19 vaccine after a federal appeals court on Wednesday rejected its challenge to patents belonging to Arbutus Biopharma Corp.</p><p><blockquote>Moderna Inc可能因其COVID-19疫苗面临专利侵权诉讼，此前联邦上诉法院周三驳回了其对Arbutus Biopharma Corp.专利的质疑。</blockquote></p><p> The Federal Circuit U.S. Court of Appeals let stand an administrative panel's findings that Arbutus' patents - which may cover technology used in the vaccines - are valid, as the science involved was not previously known.</p><p><blockquote>美国联邦巡回上诉法院维持了行政小组的调查结果，即Arbutus的专利（可能涵盖疫苗中使用的技术）是有效的，因为所涉及的科学此前并不为人所知。</blockquote></p><p> Moderna previously said in court filings that it believes Arbutus could bring a lawsuit demanding royalties from its COVID-19 vaccine if the patents were upheld.</p><p><blockquote>Moderna此前在法庭文件中表示，如果专利得到维持，它认为Arbutus可能会提起诉讼，要求其COVID-19疫苗支付特许权使用费。</blockquote></p><p> The company last month forecast 2021 sales of between $15 billion and $18 billion, and 2022 sales of between $17 billion and $22 billion, for its COVID-19 vaccine.</p><p><blockquote>该公司上个月预测其COVID-19疫苗2021年的销售额将在150亿美元至180亿美元之间，2022年的销售额将在170亿美元至220亿美元之间。</blockquote></p><p> Jefferies analyst Dennis Ding said an infringement lawsuit was possible, but could drag for years, adding that Arbutus will likely settle for a small royalty.</p><p><blockquote>杰富瑞(Jefferies)分析师丹尼斯·丁(Dennis Ding)表示，侵权诉讼是可能的，但可能会持续数年，并补充说，Arbutus可能会满足于收取少量特许权使用费。</blockquote></p><p> \"When you're thinking about the revenue opportunity from the vaccine, so just like $10 (billion) to $20 billion annually, a small low-single-digit royalty is immaterial to Moderna,\" he said.</p><p><blockquote>“当你考虑疫苗的收入机会时，就像每年100亿至200亿美元一样，少量的低个位数特许权使用费对Moderna来说并不重要，”他说。</blockquote></p><p> Both patents in question involve the so-called lipid nanoparticles that enclose the genetic material, known as messenger RNA (mRNA), in the vaccine. The technology could prove useful in developing future mRNA-based vaccines against other illnesses as well.</p><p><blockquote>这两项专利都涉及所谓的脂质纳米颗粒，这些纳米颗粒包裹着疫苗中称为信使RNA(mRNA)的遗传物质。该技术也可能有助于开发未来基于mRNA的针对其他疾病的疫苗。</blockquote></p><p> Moderna initially challenged the patents before the U.S. Patent Trial and Appeal Board, part of the federal patent office. The board agreed with Moderna that some portions of one of the patents were invalid but otherwise sided with Arbutus, and the Federal Circuit upheld its findings.</p><p><blockquote>Moderna最初向联邦专利局下属的美国专利审判和上诉委员会对这些专利提出质疑。委员会同意Moderna的观点，即其中一项专利的某些部分无效，但在其他方面站在Arbutus一边，联邦巡回法院支持其调查结果。</blockquote></p><p> The patents are licensed to Genevant Sciences Inc, a company launched in 2018 by Arbutus and Roivant Sciences Ltd. Roivant owns about 80% of Genevant and Arbutus owns the remainder.</p><p><blockquote>这些专利被授权给Genevant Sciences Inc，该公司由Arbutus和Roivant Sciences Ltd于2018年成立。Roivant拥有Genevant约80%的股份，Arbutus拥有其余股份。</blockquote></p><p> Moderna is also embroiled in a months-long patent conflict over its COVID-19 vaccine with the U.S. National Institutes of Health (NIH).</p><p><blockquote>Moderna还卷入了与美国国立卫生研究院(NIH)长达数月的COVID-19疫苗专利冲突。</blockquote></p><p> NIH has asserted that three of its scientists helped design the genetic sequence used in Moderna's multibillion-dollar vaccine and should be named on the patent application, a claim the company disagrees with.</p><p><blockquote>NIH声称，其三名科学家帮助设计了Moderna价值数十亿美元的疫苗中使用的基因序列，应该在专利申请中命名，但该公司不同意这一说法。</blockquote></p><p> The company maintains that the mRNA sequence in the company's vaccine was selected exclusively by Moderna's scientists, and without input of NIH scientists.</p><p><blockquote>该公司坚称，该公司疫苗中的mRNA序列完全由Moderna的科学家选择，没有NIH科学家的参与。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna shares dipped more than 2% in premarket trading<blockquote>Moderna股价在盘前交易中下跌超过2%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna shares dipped more than 2% in premarket trading<blockquote>Moderna股价在盘前交易中下跌超过2%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-02 17:10</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Moderna shares dipped more than 2% in premarket trading as it could be sued over vaccines as court upholds Arbutus patents.</p><p><blockquote>Moderna股价在盘前交易中下跌超过2%，因为法院支持杨梅专利，该公司可能会因疫苗问题被起诉。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/c4b23d228b24ede7e56c373ea5ecd787\" tg-width=\"853\" tg-height=\"622\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> Moderna Inc could face a patent infringement lawsuit over its COVID-19 vaccine after a federal appeals court on Wednesday rejected its challenge to patents belonging to Arbutus Biopharma Corp.</p><p><blockquote>Moderna Inc可能因其COVID-19疫苗面临专利侵权诉讼，此前联邦上诉法院周三驳回了其对Arbutus Biopharma Corp.专利的质疑。</blockquote></p><p> The Federal Circuit U.S. Court of Appeals let stand an administrative panel's findings that Arbutus' patents - which may cover technology used in the vaccines - are valid, as the science involved was not previously known.</p><p><blockquote>美国联邦巡回上诉法院维持了行政小组的调查结果，即Arbutus的专利（可能涵盖疫苗中使用的技术）是有效的，因为所涉及的科学此前并不为人所知。</blockquote></p><p> Moderna previously said in court filings that it believes Arbutus could bring a lawsuit demanding royalties from its COVID-19 vaccine if the patents were upheld.</p><p><blockquote>Moderna此前在法庭文件中表示，如果专利得到维持，它认为Arbutus可能会提起诉讼，要求其COVID-19疫苗支付特许权使用费。</blockquote></p><p> The company last month forecast 2021 sales of between $15 billion and $18 billion, and 2022 sales of between $17 billion and $22 billion, for its COVID-19 vaccine.</p><p><blockquote>该公司上个月预测其COVID-19疫苗2021年的销售额将在150亿美元至180亿美元之间，2022年的销售额将在170亿美元至220亿美元之间。</blockquote></p><p> Jefferies analyst Dennis Ding said an infringement lawsuit was possible, but could drag for years, adding that Arbutus will likely settle for a small royalty.</p><p><blockquote>杰富瑞(Jefferies)分析师丹尼斯·丁(Dennis Ding)表示，侵权诉讼是可能的，但可能会持续数年，并补充说，Arbutus可能会满足于收取少量特许权使用费。</blockquote></p><p> \"When you're thinking about the revenue opportunity from the vaccine, so just like $10 (billion) to $20 billion annually, a small low-single-digit royalty is immaterial to Moderna,\" he said.</p><p><blockquote>“当你考虑疫苗的收入机会时，就像每年100亿至200亿美元一样，少量的低个位数特许权使用费对Moderna来说并不重要，”他说。</blockquote></p><p> Both patents in question involve the so-called lipid nanoparticles that enclose the genetic material, known as messenger RNA (mRNA), in the vaccine. The technology could prove useful in developing future mRNA-based vaccines against other illnesses as well.</p><p><blockquote>这两项专利都涉及所谓的脂质纳米颗粒，这些纳米颗粒包裹着疫苗中称为信使RNA(mRNA)的遗传物质。该技术也可能有助于开发未来基于mRNA的针对其他疾病的疫苗。</blockquote></p><p> Moderna initially challenged the patents before the U.S. Patent Trial and Appeal Board, part of the federal patent office. The board agreed with Moderna that some portions of one of the patents were invalid but otherwise sided with Arbutus, and the Federal Circuit upheld its findings.</p><p><blockquote>Moderna最初向联邦专利局下属的美国专利审判和上诉委员会对这些专利提出质疑。委员会同意Moderna的观点，即其中一项专利的某些部分无效，但在其他方面站在Arbutus一边，联邦巡回法院支持其调查结果。</blockquote></p><p> The patents are licensed to Genevant Sciences Inc, a company launched in 2018 by Arbutus and Roivant Sciences Ltd. Roivant owns about 80% of Genevant and Arbutus owns the remainder.</p><p><blockquote>这些专利被授权给Genevant Sciences Inc，该公司由Arbutus和Roivant Sciences Ltd于2018年成立。Roivant拥有Genevant约80%的股份，Arbutus拥有其余股份。</blockquote></p><p> Moderna is also embroiled in a months-long patent conflict over its COVID-19 vaccine with the U.S. National Institutes of Health (NIH).</p><p><blockquote>Moderna还卷入了与美国国立卫生研究院(NIH)长达数月的COVID-19疫苗专利冲突。</blockquote></p><p> NIH has asserted that three of its scientists helped design the genetic sequence used in Moderna's multibillion-dollar vaccine and should be named on the patent application, a claim the company disagrees with.</p><p><blockquote>NIH声称，其三名科学家帮助设计了Moderna价值数十亿美元的疫苗中使用的基因序列，应该在专利申请中命名，但该公司不同意这一说法。</blockquote></p><p> The company maintains that the mRNA sequence in the company's vaccine was selected exclusively by Moderna's scientists, and without input of NIH scientists.</p><p><blockquote>该公司坚称，该公司疫苗中的mRNA序列完全由Moderna的科学家选择，没有NIH科学家的参与。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1138497635","content_text":"Moderna shares dipped more than 2% in premarket trading as it could be sued over vaccines as court upholds Arbutus patents.\n\nModerna Inc could face a patent infringement lawsuit over its COVID-19 vaccine after a federal appeals court on Wednesday rejected its challenge to patents belonging to Arbutus Biopharma Corp.\nThe Federal Circuit U.S. Court of Appeals let stand an administrative panel's findings that Arbutus' patents - which may cover technology used in the vaccines - are valid, as the science involved was not previously known.\nModerna previously said in court filings that it believes Arbutus could bring a lawsuit demanding royalties from its COVID-19 vaccine if the patents were upheld.\nThe company last month forecast 2021 sales of between $15 billion and $18 billion, and 2022 sales of between $17 billion and $22 billion, for its COVID-19 vaccine.\nJefferies analyst Dennis Ding said an infringement lawsuit was possible, but could drag for years, adding that Arbutus will likely settle for a small royalty.\n\"When you're thinking about the revenue opportunity from the vaccine, so just like $10 (billion) to $20 billion annually, a small low-single-digit royalty is immaterial to Moderna,\" he said.\nBoth patents in question involve the so-called lipid nanoparticles that enclose the genetic material, known as messenger RNA (mRNA), in the vaccine. The technology could prove useful in developing future mRNA-based vaccines against other illnesses as well.\nModerna initially challenged the patents before the U.S. Patent Trial and Appeal Board, part of the federal patent office. The board agreed with Moderna that some portions of one of the patents were invalid but otherwise sided with Arbutus, and the Federal Circuit upheld its findings.\nThe patents are licensed to Genevant Sciences Inc, a company launched in 2018 by Arbutus and Roivant Sciences Ltd. Roivant owns about 80% of Genevant and Arbutus owns the remainder.\nModerna is also embroiled in a months-long patent conflict over its COVID-19 vaccine with the U.S. National Institutes of Health (NIH).\nNIH has asserted that three of its scientists helped design the genetic sequence used in Moderna's multibillion-dollar vaccine and should be named on the patent application, a claim the company disagrees with.\nThe company maintains that the mRNA sequence in the company's vaccine was selected exclusively by Moderna's scientists, and without input of NIH scientists.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":3444,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":609888045,"gmtCreate":1638264393592,"gmtModify":1638264456117,"author":{"id":"3577793809591330","authorId":"3577793809591330","name":"SquatMachine","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577793809591330","authorIdStr":"3577793809591330"},"themes":[],"htmlText":"Didn't he say earlier it's good to go for 2022???","listText":"Didn't he say earlier it's good to go for 2022???","text":"Didn't he say earlier it's good to go for 2022???","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/609888045","repostId":"1176161322","repostType":2,"repost":{"id":"1176161322","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1638263039,"share":"https://www.laohu8.com/m/news/1176161322?lang=zh_CN&edition=full","pubTime":"2021-11-30 17:03","market":"us","language":"en","title":"Moderna stock slid 1.5% in premarket trading<blockquote>Moderna股价在盘前交易中下跌1.5%</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1176161322","media":"Tiger Newspress","summary":"Moderna stock slid 1.5% in premarket trading as Moderna CEO said vaccines likely less effective agai","content":"<p>Moderna stock slid 1.5% in premarket trading as Moderna CEO said vaccines likely less effective against Omicron.</p><p><blockquote>Moderna首席执行官表示疫苗对奥密克戎病毒的效果可能较差，Moderna股价在盘前交易中下跌1.5%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/dba337733c64956ca75b06171ffc5745\" tg-width=\"851\" tg-height=\"621\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> The head of drugmaker Moderna said COVID-19 vaccines are unlikely to be as effective against the Omicron variant of the coronavirus as they have been previously, sparking fresh worry in financial markets about the trajectory of the pandemic.</p><p><blockquote>制药商Moderna的负责人表示，COVID-19疫苗不太可能像以前那样有效对抗冠状病毒的奥密克戎变种，这引发了金融市场对大流行轨迹的新担忧。</blockquote></p><p> \"There is no world, I think, where (the effectiveness) is the same level . . . we had with Delta,\" Moderna Chief Executive Stéphane Bancel told the Financial Times in an interview.</p><p><blockquote>Moderna首席执行官斯特凡·班塞尔(Stéphane Bancel)在接受英国《金融时报》采访时表示：“我认为，没有一个世界的（有效性）与我们与达美航空的水平相同。”</blockquote></p><p> \"I think it's going to be a material drop. I just don't know how much because we need to wait for the data. But all the scientists I've talked to . . . are like 'this is not going to be good.'\"</p><p><blockquote>“我认为这将是一次物质下降。我只是不知道有多少，因为我们需要等待数据。但我交谈过的所有科学家……都像‘这不会有好结果’。”</blockquote></p><p> Vaccine resistance could lead to more sickness and hospitalisations and prolong the pandemic, and his comments triggered selling in growth-exposed assets like oil, stocks and the Australian dollar.</p><p><blockquote>疫苗耐药性可能会导致更多的疾病和住院，并延长疫情，他的言论引发了石油、股票和澳元等增长资产的抛售。</blockquote></p><p> Bancel added that the high number of mutations on the protein spike the virus uses to infect human cells meant it was likely the current crop of vaccines would need to be modified.</p><p><blockquote>Bancel补充说，病毒用于感染人类细胞的蛋白质刺突上的大量突变意味着当前的疫苗可能需要进行修改。</blockquote></p><p> He had earlier said on CNBC that it could take months to begin shipping a vaccine that does work against Omicron.</p><p><blockquote>他早些时候在CNBC上表示，可能需要几个月的时间才能开始运送针对奥密克戎病毒的疫苗。</blockquote></p><p> Fear of the new variant, despite a lack of information about its severity, has already triggered delays to some economic reopening plans and the reimposition of some travel and movement restrictions.</p><p><blockquote>尽管缺乏关于其严重性的信息，但对新变种的恐惧已经引发了一些经济重新开放计划的推迟，以及一些旅行和行动限制的重新实施。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna stock slid 1.5% in premarket trading<blockquote>Moderna股价在盘前交易中下跌1.5%</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna stock slid 1.5% in premarket trading<blockquote>Moderna股价在盘前交易中下跌1.5%</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-11-30 17:03</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Moderna stock slid 1.5% in premarket trading as Moderna CEO said vaccines likely less effective against Omicron.</p><p><blockquote>Moderna首席执行官表示疫苗对奥密克戎病毒的效果可能较差，Moderna股价在盘前交易中下跌1.5%。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/dba337733c64956ca75b06171ffc5745\" tg-width=\"851\" tg-height=\"621\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> The head of drugmaker Moderna said COVID-19 vaccines are unlikely to be as effective against the Omicron variant of the coronavirus as they have been previously, sparking fresh worry in financial markets about the trajectory of the pandemic.</p><p><blockquote>制药商Moderna的负责人表示，COVID-19疫苗不太可能像以前那样有效对抗冠状病毒的奥密克戎变种，这引发了金融市场对大流行轨迹的新担忧。</blockquote></p><p> \"There is no world, I think, where (the effectiveness) is the same level . . . we had with Delta,\" Moderna Chief Executive Stéphane Bancel told the Financial Times in an interview.</p><p><blockquote>Moderna首席执行官斯特凡·班塞尔(Stéphane Bancel)在接受英国《金融时报》采访时表示：“我认为，没有一个世界的（有效性）与我们与达美航空的水平相同。”</blockquote></p><p> \"I think it's going to be a material drop. I just don't know how much because we need to wait for the data. But all the scientists I've talked to . . . are like 'this is not going to be good.'\"</p><p><blockquote>“我认为这将是一次物质下降。我只是不知道有多少，因为我们需要等待数据。但我交谈过的所有科学家……都像‘这不会有好结果’。”</blockquote></p><p> Vaccine resistance could lead to more sickness and hospitalisations and prolong the pandemic, and his comments triggered selling in growth-exposed assets like oil, stocks and the Australian dollar.</p><p><blockquote>疫苗耐药性可能会导致更多的疾病和住院，并延长疫情，他的言论引发了石油、股票和澳元等增长资产的抛售。</blockquote></p><p> Bancel added that the high number of mutations on the protein spike the virus uses to infect human cells meant it was likely the current crop of vaccines would need to be modified.</p><p><blockquote>Bancel补充说，病毒用于感染人类细胞的蛋白质刺突上的大量突变意味着当前的疫苗可能需要进行修改。</blockquote></p><p> He had earlier said on CNBC that it could take months to begin shipping a vaccine that does work against Omicron.</p><p><blockquote>他早些时候在CNBC上表示，可能需要几个月的时间才能开始运送针对奥密克戎病毒的疫苗。</blockquote></p><p> Fear of the new variant, despite a lack of information about its severity, has already triggered delays to some economic reopening plans and the reimposition of some travel and movement restrictions.</p><p><blockquote>尽管缺乏关于其严重性的信息，但对新变种的恐惧已经引发了一些经济重新开放计划的推迟，以及一些旅行和行动限制的重新实施。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1176161322","content_text":"Moderna stock slid 1.5% in premarket trading as Moderna CEO said vaccines likely less effective against Omicron.\n\nThe head of drugmaker Moderna said COVID-19 vaccines are unlikely to be as effective against the Omicron variant of the coronavirus as they have been previously, sparking fresh worry in financial markets about the trajectory of the pandemic.\n\"There is no world, I think, where (the effectiveness) is the same level . . . we had with Delta,\" Moderna Chief Executive Stéphane Bancel told the Financial Times in an interview.\n\"I think it's going to be a material drop. I just don't know how much because we need to wait for the data. But all the scientists I've talked to . . . are like 'this is not going to be good.'\"\nVaccine resistance could lead to more sickness and hospitalisations and prolong the pandemic, and his comments triggered selling in growth-exposed assets like oil, stocks and the Australian dollar.\nBancel added that the high number of mutations on the protein spike the virus uses to infect human cells meant it was likely the current crop of vaccines would need to be modified.\nHe had earlier said on CNBC that it could take months to begin shipping a vaccine that does work against Omicron.\nFear of the new variant, despite a lack of information about its severity, has already triggered delays to some economic reopening plans and the reimposition of some travel and movement restrictions.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":3279,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":837488653,"gmtCreate":1629905341372,"gmtModify":1633681558541,"author":{"id":"3577793809591330","authorId":"3577793809591330","name":"SquatMachine","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577793809591330","authorIdStr":"3577793809591330"},"themes":[],"htmlText":"lets get some volume in.","listText":"lets get some volume in.","text":"lets get some volume in.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/837488653","repostId":"1196509788","repostType":2,"repost":{"id":"1196509788","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1629899168,"share":"https://www.laohu8.com/m/news/1196509788?lang=zh_CN&edition=full","pubTime":"2021-08-25 21:46","market":"us","language":"en","title":"Some meme stocks slipped in morning trading<blockquote>一些模因股票早盘下跌</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1196509788","media":"Tiger Newspress","summary":"Some meme stocks slipped in morning trading.GameStop,AMC Entertainment,Express,KOSS and Robinhood fe","content":"<p>Some meme stocks slipped in morning trading.GameStop,AMC Entertainment,Express,KOSS and Robinhood fell between 1% and 7% while Naked Brand Group surged 7.5%.</p><p><blockquote>一些meme股票在早盘交易中下跌。GameStop、AMC院线、Express、KOSS和Robinhood下跌1%至7%，而Naked Brand Group则飙升7.</blockquote></p><p> <img src=\"https://static.tigerbbs.com/3cd4a1e47831725ac5c3611834284345\" tg-width=\"356\" tg-height=\"723\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> GameStop stock was slipping after gaining 28% on Tuesday. But the revival of the meme-stock trade could be good news for small-cap stocks generally.</p><p><blockquote>游戏驿站股价在周二上涨28%后正在下跌。但模因股票交易的复苏对于小盘股来说可能是个好消息。</blockquote></p><p> It’s not much of a move compared with Tuesday’s surge, but with meme stocks, one never can tell.</p><p><blockquote>与周二的飙升相比，这并不算太大，但对于模因股票来说，人们永远无法判断。</blockquote></p><p> GameStop stock had dropped nearly 50% since peaking in early June, but erased 40% of that drop in one day. It also looks to have cleared resistance at about $200, which means there could be more upside ahead. Don’t be surprised if $200 becomes support.</p><p><blockquote>自6月初见顶以来，游戏驿站股价已下跌近50%，但一天之内就抹去了40%的跌幅。它看起来也已经清除了200美元左右的阻力，这意味着未来可能还有更多上涨空间。如果200美元成为支撑，不要感到惊讶。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/1ca853dd891fce6c2ec9d0ecf67497eb\" tg-width=\"952\" tg-height=\"627\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> GameStop wasn’t the only meme stock on the move Tuesday.AMC Entertainment(AMC) gained 20%, and like GameStop, it appeared to clear resistance, though not quite as cleanly.</p><p><blockquote>游戏驿站并不是周二唯一一只上涨的模因股票。AMC Entertainment(AMC)上涨了20%，与游戏驿站一样，它似乎清除了阻力，尽管没有那么干净。</blockquote></p><p> For those wondering why we care about these stocks, consider this: AMC is the largest position in the iShares Russell 2000 ETF(IWM), even if that means it’s just 0.5% of the index. If the meme stocks keep rising that could be good news for small-caps, which have gone nowhere since February.</p><p><blockquote>对于那些想知道我们为什么关心这些股票的人，请考虑一下：AMC是iShares Russell 2000 ETF(IWM)中最大的头寸，即使这意味着它仅占该指数的0.5%。如果模因股票继续上涨，这对小盘股来说可能是个好消息，因为自二月份以来，小盘股就毫无进展。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/d97157fe74c2c1baef4735a0dbbc9d67\" tg-width=\"960\" tg-height=\"639\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> “Nice bounce …but a lot still to prove,” writes Bay Crest Partners’ Jonathan Krinsky. “IWM closing above $225 would send a strong bullish message for small-caps, and suggest the now seven-month consolidation is, in fact, resolving higher.”</p><p><blockquote>“反弹不错……但仍有很多需要证明，”Bay Crest Partners的乔纳森·克林斯基(Jonathan Krinsky)写道。“IWM收盘价高于225美元将向小盘股发出强烈的看涨信息，并表明目前七个月的盘整实际上正在走高。”</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Some meme stocks slipped in morning trading<blockquote>一些模因股票早盘下跌</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSome meme stocks slipped in morning trading<blockquote>一些模因股票早盘下跌</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-08-25 21:46</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Some meme stocks slipped in morning trading.GameStop,AMC Entertainment,Express,KOSS and Robinhood fell between 1% and 7% while Naked Brand Group surged 7.5%.</p><p><blockquote>一些meme股票在早盘交易中下跌。GameStop、AMC院线、Express、KOSS和Robinhood下跌1%至7%，而Naked Brand Group则飙升7.</blockquote></p><p> <img src=\"https://static.tigerbbs.com/3cd4a1e47831725ac5c3611834284345\" tg-width=\"356\" tg-height=\"723\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> GameStop stock was slipping after gaining 28% on Tuesday. But the revival of the meme-stock trade could be good news for small-cap stocks generally.</p><p><blockquote>游戏驿站股价在周二上涨28%后正在下跌。但模因股票交易的复苏对于小盘股来说可能是个好消息。</blockquote></p><p> It’s not much of a move compared with Tuesday’s surge, but with meme stocks, one never can tell.</p><p><blockquote>与周二的飙升相比，这并不算太大，但对于模因股票来说，人们永远无法判断。</blockquote></p><p> GameStop stock had dropped nearly 50% since peaking in early June, but erased 40% of that drop in one day. It also looks to have cleared resistance at about $200, which means there could be more upside ahead. Don’t be surprised if $200 becomes support.</p><p><blockquote>自6月初见顶以来，游戏驿站股价已下跌近50%，但一天之内就抹去了40%的跌幅。它看起来也已经清除了200美元左右的阻力，这意味着未来可能还有更多上涨空间。如果200美元成为支撑，不要感到惊讶。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/1ca853dd891fce6c2ec9d0ecf67497eb\" tg-width=\"952\" tg-height=\"627\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> GameStop wasn’t the only meme stock on the move Tuesday.AMC Entertainment(AMC) gained 20%, and like GameStop, it appeared to clear resistance, though not quite as cleanly.</p><p><blockquote>游戏驿站并不是周二唯一一只上涨的模因股票。AMC Entertainment(AMC)上涨了20%，与游戏驿站一样，它似乎清除了阻力，尽管没有那么干净。</blockquote></p><p> For those wondering why we care about these stocks, consider this: AMC is the largest position in the iShares Russell 2000 ETF(IWM), even if that means it’s just 0.5% of the index. If the meme stocks keep rising that could be good news for small-caps, which have gone nowhere since February.</p><p><blockquote>对于那些想知道我们为什么关心这些股票的人，请考虑一下：AMC是iShares Russell 2000 ETF(IWM)中最大的头寸，即使这意味着它仅占该指数的0.5%。如果模因股票继续上涨，这对小盘股来说可能是个好消息，因为自二月份以来，小盘股就毫无进展。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/d97157fe74c2c1baef4735a0dbbc9d67\" tg-width=\"960\" tg-height=\"639\" referrerpolicy=\"no-referrer\"></p><p><blockquote></blockquote></p><p> “Nice bounce …but a lot still to prove,” writes Bay Crest Partners’ Jonathan Krinsky. “IWM closing above $225 would send a strong bullish message for small-caps, and suggest the now seven-month consolidation is, in fact, resolving higher.”</p><p><blockquote>“反弹不错……但仍有很多需要证明，”Bay Crest Partners的乔纳森·克林斯基(Jonathan Krinsky)写道。“IWM收盘价高于225美元将向小盘股发出强烈的看涨信息，并表明目前七个月的盘整实际上正在走高。”</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GME":"游戏驿站","EXPR":"Express, Inc.","AMC":"AMC院线","KOSS":"高斯电子"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1196509788","content_text":"Some meme stocks slipped in morning trading.GameStop,AMC Entertainment,Express,KOSS and Robinhood fell between 1% and 7% while Naked Brand Group surged 7.5%.\n\nGameStop stock was slipping after gaining 28% on Tuesday. But the revival of the meme-stock trade could be good news for small-cap stocks generally.\nIt’s not much of a move compared with Tuesday’s surge, but with meme stocks, one never can tell.\nGameStop stock had dropped nearly 50% since peaking in early June, but erased 40% of that drop in one day. It also looks to have cleared resistance at about $200, which means there could be more upside ahead. Don’t be surprised if $200 becomes support.\n\nGameStop wasn’t the only meme stock on the move Tuesday.AMC Entertainment(AMC) gained 20%, and like GameStop, it appeared to clear resistance, though not quite as cleanly.\nFor those wondering why we care about these stocks, consider this: AMC is the largest position in the iShares Russell 2000 ETF(IWM), even if that means it’s just 0.5% of the index. If the meme stocks keep rising that could be good news for small-caps, which have gone nowhere since February.\n\n“Nice bounce …but a lot still to prove,” writes Bay Crest Partners’ Jonathan Krinsky. “IWM closing above $225 would send a strong bullish message for small-caps, and suggest the now seven-month consolidation is, in fact, resolving higher.”","news_type":1,"symbols_score_info":{"NAKD":0.9,"KOSS":0.9,"AMC":0.9,"GME":0.9,"EXPR":0.9}},"isVote":1,"tweetType":1,"viewCount":1654,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":803980571,"gmtCreate":1627400893493,"gmtModify":1633765337915,"author":{"id":"3577793809591330","authorId":"3577793809591330","name":"SquatMachine","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3577793809591330","authorIdStr":"3577793809591330"},"themes":[],"htmlText":"Buy the dip on NIO?","listText":"Buy the dip on NIO?","text":"Buy the dip on NIO?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/803980571","repostId":"1191522112","repostType":2,"repost":{"id":"1191522112","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1627399476,"share":"https://www.laohu8.com/m/news/1191522112?lang=zh_CN&edition=full","pubTime":"2021-07-27 23:24","market":"us","language":"zh","title":"中概股跌幅持续扩大，小鹏汽车跌超15%","url":"https://stock-news.laohu8.com/highlight/detail?id=1191522112","media":"老虎资讯综合","summary":"7月27日，中概股跌幅持续扩大，小鹏汽车跌超15%，理想汽车跌超11%，拼多多跌超10%，蔚来、哔哩哔哩跌超9%，阿里巴巴、京东、百度跌超5%.","content":"<p>7月27日，中概股跌幅持续扩大，<a href=\"https://laohu8.com/S/XPEV\">小鹏汽车</a>跌超15%，<a href=\"https://laohu8.com/S/LI\">理想汽车</a>跌超11%，<a href=\"https://laohu8.com/S/PDD\">拼多多</a>跌超10%，<a href=\"https://laohu8.com/S/NIO\">蔚来</a>、<a href=\"https://laohu8.com/S/BILI\">哔哩哔哩</a>跌超9%，<a href=\"https://laohu8.com/S/BABA\">阿里巴巴</a>、<a href=\"https://laohu8.com/S/JD\">京东</a>、<a href=\"https://laohu8.com/S/BIDU\">百度</a>跌超5%.</p>\n<p><img src=\"https://static.tigerbbs.com/fa78e3c7e10ba06edbd438da6686c91d\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>中概股跌幅持续扩大，小鹏汽车跌超15%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n中概股跌幅持续扩大，小鹏汽车跌超15%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2021-07-27 23:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>7月27日，中概股跌幅持续扩大，<a href=\"https://laohu8.com/S/XPEV\">小鹏汽车</a>跌超15%，<a href=\"https://laohu8.com/S/LI\">理想汽车</a>跌超11%，<a href=\"https://laohu8.com/S/PDD\">拼多多</a>跌超10%，<a href=\"https://laohu8.com/S/NIO\">蔚来</a>、<a href=\"https://laohu8.com/S/BILI\">哔哩哔哩</a>跌超9%，<a href=\"https://laohu8.com/S/BABA\">阿里巴巴</a>、<a href=\"https://laohu8.com/S/JD\">京东</a>、<a href=\"https://laohu8.com/S/BIDU\">百度</a>跌超5%.</p>\n<p><img src=\"https://static.tigerbbs.com/fa78e3c7e10ba06edbd438da6686c91d\" tg-width=\"840\" tg-height=\"470\" referrerpolicy=\"no-referrer\"></p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/c7da52addfd52fb216bcf87283f43750","relate_stocks":{"NIO":"蔚来","XPEV":"小鹏汽车","BABA":"阿里巴巴","PDD":"拼多多","QNETCN":"纳斯达克中美互联网老虎指数","LI":"理想汽车","TTTN":"老虎中美互联网巨头ETF","BILI":"哔哩哔哩","BIDU":"百度","09868":"小鹏汽车-W","JD":"京东"},"is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1191522112","content_text":"7月27日，中概股跌幅持续扩大，小鹏汽车跌超15%，理想汽车跌超11%，拼多多跌超10%，蔚来、哔哩哔哩跌超9%，阿里巴巴、京东、百度跌超5%.","news_type":1,"symbols_score_info":{"09868":0.9,"BIDU":0.9,"TTTN":0.9,"LI":0.9,"NIO":0.9,"BABA":0.9,"QNETCN":0.9,"PDD":0.9,"JD":0.9,"XPEV":0.9,"BILI":0.9}},"isVote":1,"tweetType":1,"viewCount":1473,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":false}